A pharmaceutical company submitted a possible vaccine to combat the coronavirus in humans to the analysis of researchers from the United States government.
The actions of Moderna, a biotechnology company, skyrocketed early Tuesday, a day after the company said it sent vials to the National Institute of Allergic and Infectious Diseases for testing at early stages in the United States.
More than 80,000 people have been infected worldwide by the viral outbreak that began late last year in China. A total of 35 cases have been reported in the United States.RELATED
More than 2,600 people have died from the virus in mainland China, including a US citizen.
Shares of Moderna Inc., based in Cambridge, Massachusetts, increased by almost 16% in the electronic exchange prior to the opening of the US stock exchanges.
The stock began trading at the end of 2018 and set a maximum historical price of $ 29.79 last April, according to FactSet.